Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2016

Summary


Global Markets Direct's, 'Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2016', provides an overview of the Uterine Leiomyoma (Uterine Fibroids) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids)
- The report reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Uterine Leiomyoma (Uterine Fibroids) therapeutics and enlists all their major and minor projects
- The report assesses Uterine Leiomyoma (Uterine Fibroids) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids)

Reasons to buy


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Uterine Leiomyoma (Uterine Fibroids) Overview 8
Therapeutics Development 9
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Overview 9
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis 10
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Development by Companies 11
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Investigation by Universities/Institutes 12
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Uterine Leiomyoma (Uterine Fibroids) - Products under Development by Companies 16
Uterine Leiomyoma (Uterine Fibroids) - Products under Investigation by Universities/Institutes 17
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development 18
AbbVie Inc. 18
Addex Therapeutics Ltd 19
Bayer AG 20
BioSpecifics Technologies Corp. 21
Dongkook Pharmaceutical Co., Ltd. 22
Euroscreen S.A. 23
Kissei Pharmaceutical Co., Ltd. 24
Laboratoire HRA Pharma 25
Repros Therapeutics Inc. 26
Takeda Pharmaceutical Company Limited 27
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
collagenase clostridium histolyticum - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Drugs for Endometriosis and Uterine Fibroids - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
elagolix sodium - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ESN-364 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
EVE-104 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
KLH-2109 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
relugolix - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
telapristone acetate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
triptorelin biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ulipristal acetate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
vilaprisan - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
VPE-001 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
VPEA-004 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Uterine Leiomyoma (Uterine Fibroids) - Recent Pipeline Updates 61
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects 81
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products 82
Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones 83
Featured News & Press Releases 83
Jan 28, 2016: AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids 83
Dec 21, 2015: Repros Updates Proellex Program 83
Nov 12, 2015: Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex in Women With Symptomatic Uterine Fibroid Bleeding 83
Oct 09, 2015: Full Results of PEARL IV Study Presented at the European Society of Gynaecological Endoscopy Congress Confirms the Efficacy of Ulipristal Acetate 5 mg for the Long Term Management of Uterine Fibroids 84
Sep 16, 2015: Abbvie Announces Plans To Proceed To Phase 3 Evaluation Of Elagolix In Patients With Uterine Fibroids 85
Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients 86
Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA 87
Dec 29, 2014: Repros Initiates Two Phase 2B Uterine Fibroid Studies 87
Oct 16, 2014: BioSpecifics Technologies Announces Presentation of Encouraging Preclinical Data for CCH from Collaborative Uterine Fibroid Study with Duke Medicine 88
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 89
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2016 9
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc., H1 2016 18
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H1 2016 19
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H1 2016 20
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp., H1 2016 21
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2016 22
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Euroscreen S.A., H1 2016 23
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 24
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Laboratoire HRA Pharma, H1 2016 25
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc., H1 2016 26
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 27
Assessment by Monotherapy Products, H1 2016 28
Number of Products by Stage and Target, H1 2016 30
Number of Products by Stage and Mechanism of Action, H1 2016 32
Number of Products by Stage and Route of Administration, H1 2016 34
Number of Products by Stage and Molecule Type, H1 2016 36
Uterine Leiomyoma (Uterine Fibroids) Therapeutics - Recent Pipeline Updates, H1 2016 61
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2016 81
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1 2016 82